FDA decision: Iberdomide by Celgene (this year)

FDA decision: Iberdomide by Celgene (this year)

$0 vol

Order book

Market Rules

Resolves Yes if the FDA's decision on Iberdomide by Celgene in 2026 is a full approval or an accelerated approval.Outcome verified from AppliedXL.

This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued.

Iberdomide is an experimental oral pill developed by Bristol Myers Squibb (under the Celgene banner) to treat multiple myeloma, a cancer of the blood's plasma cells. Think of it as a precision "molecular crowbar" — it hijacks the cell's own waste-disposal machinery to break down specific proteins that cancer cells depend on to survive and multiply. By forcing the destruction of those proteins, iberdomide aims to slow or stop the growth of myeloma cells.

Note: this event is mutually exclusive.

Timeline and payout

Market openJun 17, 2026 · 5:00pm EDT

Market closesAfter the outcome occurs

Projected payout30 minutes after closing

This market will close early if the FDA issues a decision on Iberdomide before Jan 1, 2027 Otherwise, it closes by Dec 31, 2026 at 11:59pm EST.

SeriesKXIBERDOMIDE

EventKXIBERDOMIDE-27

MarketKXIBERDOMIDE-27-Y

Insider trading is prohibited

The following are prohibited from trading this contract:

Persons who are employed by any of the Source Agencies are not permitted to trade on the Contract.
Persons who hold any material, non-public information on the Underlying are not permitted to trade on the Contract.